Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3355 in GERD patients with partial response to PPI
NCT01043185Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lesogaberan in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Started Dec 2009; status: completed.
02
Drugs
lesogaberan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01043185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01043185.